Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In the Functional Materials business, revenue and earnings increased due to higher sales volumes of inulin and collagen, strong overseas sales, and expansion into new markets. In the Sugars business, higher logistics costs restrained earnings. For the next fiscal year, higher costs and the absence of the gain on the sale of investment securities are expected.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥28,491 million (YoY +1.0%) |
| Operating profit | ¥3,528 million (YoY +9.2%) |
| Ordinary income | ¥3,742 million (YoY +2.5%) |
| Profit attributable to owners of the parent | ¥3,176 million (YoY +11.6%) |
| Net income per share | ¥61.92 |
| Operating Margin | 12.4% |
| Equity ratio | End of the current fiscal period 72.0% / End of previous period 70.6% |
| Total assets | ¥38,677 million |
| Net assets | ¥27,900 million |
| Cash flows from operating activities | ¥3,150 million |
| Cash flows from investing activities | ¥-1,705 million |
| Cash flows from financing activities | ¥-931 million |
| Cash and cash equivalents at end of period | ¥7,243 million |
| Full-year earnings forecast | Net Sales ¥29,700 million (YoY +4.2%) / Operating profit ¥3,300 million (YoY -6.5%) / Ordinary income ¥3,500 million (YoY -6.5%) / Net income ¥2,500 million (YoY -21.3%) |
| Annual Dividend Forecast | ¥36.00 (¥18.00 after reflecting the stock split) → ¥19.00（+5.6%） |
| Payout ratio | 29.1% (fiscal year ended March 2026) / 39.0% (forecast for fiscal year ending March 2027) |
| Segment revenue | Sugars ¥13,493 million (YoY -2.3%), Functional ingredients ¥14,121 million (YoY +4.7%), Real Estate ¥632 million (YoY -3.0%) |
| Segment profit | Sugars ¥2,479 million (YoY -2.0%), Functional ingredients ¥1,644 million (YoY +28.0%), Real Estate ¥579 million (YoY 0.0%) |
| Depreciation and amortization | ¥194 million |
| Impairment loss | None recorded for the current fiscal year (-) |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥0 million, Gain on sale of investment securities ¥518 million / Extraordinary loss Loss on Disposal of Fixed Assets ¥0 million, Impairment loss on investment securities ¥0 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name No |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 51,437,400 |
| Treasury Shares at Period-End | 137,228 |
| Factors Behind Changes in Business Performance | In the Functional Materials business, revenue and earnings increased due to higher sales volumes of inulin and collagen, strong overseas sales, and expansion into new markets. In the Sugars business, higher logistics costs restrained earnings. For the next fiscal year, higher costs and the absence of the gain on the sale of investment securities are expected. |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.For the fiscal year ended March 2026, sales volumes of inulin and collagen increased in the Functional Materials business, while overseas sales and expansion into new markets also contributed. In the Sugars business, however, higher logistics costs restrained earnings. For the fiscal year ending March 2027, operating income is expected to decline due to higher costs, while net income is expected to decrease due to the absence of the gain on the sale of investment securities recorded in the previous fiscal year.